ReviewMicrobial biotechnology2010
Revolutionizing membrane protein overexpression in bacteria.
Review in Microbial biotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 68 citations in OpenAlex.
- Detergent exchange from lipid nanoparticles into detergent micelles unlocks a tool for biochemical and kinetic characterization of membrane proteins.bioRxiv : the preprint server for biology · 2025Article
- A Chromosomally Integrated T7 RNA Polymerase Enables T7-Derived Expression inJournal of microbiology and biotechnology · 2025Article
- Applications of protein engineering in the microbial synthesis of plant triterpenoids.Synthetic and systems biotechnology · 2023Review
- Review
- An improved fluorescent tag and its nanobodies for membrane protein expression, stability assay, and purification.Communications biology · 2020Article
- A carotenoid-deficient mutant of the plant-associated microbe Pantoea sp. YR343 displays an altered membrane proteome.Scientific reports · 2020Article
- High-level Production of Recombinant Membrane Proteins Using the EngineeredBio-protocol · 2020Article
- Emerging molecular biology tools and strategies for engineering natural product biosynthesis.Metabolic engineering communications · 2020Review
- Production of drug metabolites by human FMO3 in Escherichia coli.Microbial cell factories · 2020Article
- Expression of Single Chain Variable Fragment (scFv) Molecules in Plants: A Comprehensive Update.Molecular biotechnology · 2020Review
- Mutations in sigma 70 transcription factor improves expression of functional eukaryotic membrane proteins in Escherichia coli.Scientific reports · 2019Article
- Current Advances in Studying Clinically Relevant Transporters of the Solute Carrier (SLC) Family by Connecting Computational Modeling and Data Science.Computational and structural biotechnology journal · 2019Review
- Expression of Leptospira membrane proteins Signal Peptidase (SP) and Leptospira Endostatin like A (Len A) in BL-21(DE3) is toxic to the host cells.Journal, genetic engineering & biotechnology · 2018Article
- Prediction and validation of the structural features of Ov58GPCR, an immunogenic determinant of Onchocerca volvulus.PloS one · 2018Article
- Improving membrane protein expression by optimizing integration efficiency.The Journal of biological chemistry · 2017Article
- Pseudomonas stutzeri as an alternative host for membrane proteins.Microbial cell factories · 2017Article
- Isolating Escherichia coli strains for recombinant protein production.Cellular and molecular life sciences : CMLS · 2017Review
- A Link between Integral Membrane Protein Expression and Simulated Integration Efficiency.Cell reports · 2016Article
- Dynamic interplay of multidrug transporters with TolC for isoprenol tolerance in Escherichia coli.Scientific reports · 2015Article
- High-level production of membrane proteins in E. coli BL21(DE3) by omitting the inducer IPTG.Microbial cell factories · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bacterium Escherichia coli is the most widely used expression host for overexpression trials of membrane proteins. Usually, different strains, culture conditions and expression regimes are screened for to identify the optimal overexpression strategy. However, yields are often not satisfactory, especially for eukaryotic membrane proteins. This has initiated a revolution of membrane protein overexpression in bacteria. Recent studies have shown that it is feasible to (i) engineer or select for E. coli strains with strongly improved membrane protein overexpression characteristics, (ii) use bacteria other than E. coli for the expression of membrane proteins, (iii) engineer or select for membrane protein variants that retain functionality but express better than the wild-type protein, and (iv) express membrane proteins using E. coli-based cell-free systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.